Share this video  

ESMO WCGIC 2020 | Systemic therapies for advanced HCC

Arndt Vogel, MD, Hannover Medical School, Hanover, Germany, explores future therapies and systemic treatments for advanced hepatocellular carcinoma (HCC), including combination therapies and approaches involving immuno-oncology. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).


Arndt Vogel, MD has had a speaker, consultancy and advisory role at Amgen, Roche, Bayer, Sanofi, BMS, Lilly, Novartis, EISAI, AstraZeneca, Merck, Incyte, Ipsen, PierreFabre, MSD, Sirtex, BTG, Servier, and Terumo.